There may be an increased risk of infections associated with drugs used to treat autoimmune disorders such as Rheumatoid Arthritis or Inflammatory Bowel Disease. Drugs known as tumor necrosis factor (TNF) inhibitors, for example, may lower the ability of the immune system to fight infections.
The Washington Biotech In Vivo models for evaluation of enhanced susceptibility to infection associated with drug dosage use Listeria monocytogenes or Candida albicans infectivity in mice as convenient and reliable study mechanisms.
- Balb/c mice infectivity
- Study duration: 10 days
- Readouts: mortality, toxicity signs, bacterial CFU (organ, blood)
Pancreatic Injury
Therapy with popular drugs for treatment of diabetes, for example, have raised questions of possible side effects leading to serious harm to the pancreas in the form of panreatitis or pancreatic cancer. Washington Biotech's Acute Pancreatitis Model (APM) provides an In Vivo quantitative measure of drug effects on the pancreas.
Our APM Model in mice evaluates effects of therapeutic or prophylactic drug treatment on pancreatic function.
- Balb/c mice
- Caerulein-induced acute pancreatitis
- Study duration: 10 days
- Readouts: plasma amylase, pancreas weight, pancreatic tissue MPO and histopathology
Washington Biotech has a wide variety of In Vivo models for drug efficacy treatments of inflammatory diseases and extensive experience in study design/interpretation/controls/reference drugs:
